With regards to the first experiment, the results showed that an increased dosage of lipopolysaccharide (LPS) increased the levels of inflammotin proteins found in the body. The Bonferroni Correction indicated that the smallest dosage (5 mg) resulted in an increase in inflammotin protein levels which was proved by the significant difference between the 0 mg to 5 mg dosages. Although there was a high variance among the test subjects who took higher doses, each increasing dosage of LPS resulted in statistical significance.
Regarding the second experiment performed on rat subjects, 0mg and 10mg doses were given to a two groups of five rat subjects. It was found that there was no significant difference calculated upon the application of an unpaired t-test because the t-test value (0.86) was greater than the 0.05 p-value.
When analyzing the data between the two experiments, it can be stated that there is no significant impact of LPS on the rat subjects; however, there was a significant difference between the groups of the human subjects. It can be inferred that the human body is more sensitive to LPS than the body of a rat. Future experiments could be performed that involve a higher dosage of LPS given to rats if justification is needed to prove whether or not the body of a rat is significantly sensitive to the chemical compound lipopolysaccharide.